SCHEMBL3591723

SCHEMBL3591723

[c]1cnn(-c2nc3ccccc3[nH]2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.51
EGLN1 Q9GZT9 1/20 0.50
BCHE P06276 2/20 0.49
ACHE P22303 2/20 0.49
TP53 P04637 4/20 0.46
AURKA O14965 2/20 0.45
RAB9A P51151 5/20 0.44
KDM4E B2RXH2 4/20 0.44
NPC1 O15118 3/20 0.44
PAX8 Q06710 2/20 0.44
TRPC3 Q13507 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 2/20 0.44
PKM P14618 2/20 0.44
ABCB11 O95342 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALKBH3 Q96Q83 3/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL546101 0.75 EGLN1 (0.51) HTR3AEGLN1BCHEACHETP53
SCHEMBL11030252 0.73 BCHE (0.49) HTR3AEGLN1BCHEACHETP53
SCHEMBL9554794 0.72 BCHE (0.54) HTR3AEGLN1BCHEACHETP53
SCHEMBL17054456 0.71 EGLN1 (0.51) HTR3AEGLN1BCHEACHETP53
SCHEMBL7027117 0.71 HTR3A (0.53) HTR3AEGLN1BCHEACHETP53
SCHEMBL7018102 0.71 BCHE (0.50) HTR3AEGLN1BCHEACHETP53
SCHEMBL18321301 0.71 EGLN1 (0.62) HTR3AEGLN1BCHEACHETP53
SCHEMBL752730 0.70 BCHE (0.49) HTR3AEGLN1BCHEACHETP53
Hydrochloric Acid SCHEMBL18321261 0.70 EGLN1 (0.60) HTR3AEGLN1BCHEACHETP53
SCHEMBL3389271 0.69 BCHE (0.56) HTR3ABCHEACHETP53AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
EP-1836188-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES Astex Therapeutics Limited (GB) 2007-09-26 EP disclosed
WO-2006070198-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES CDK1, CDK3, CDK13 HTR3A 1162/4885EGLN1 3129/4885BCHE 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.